Literature DB >> 19836365

Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes.

Matthew O Lindeblad1, Kenneth S Bauer, Alexander D Zakharov, Judith M Hill, Jonathan S Green, Brian F Thomas, Arthur Schwartz, Izet M Kapetanovic, Alexander Lyubimov.   

Abstract

The purpose of this work was to compare the pharmacokinetics (PK) and tissue distribution of [14C]fluasterone following intravenous (iv), subcutaneous (sc) and oral (po) administration in male Beagle dogs. The main goal of the investigation was to discover if non-oral routes would alter parameters observed in this study following the administration of [14C]fluasterone. The oral formulation had a lower bioavailability (47%) compared to the sc formulation (84%). Po and sc administration resulted in a similar t(max); however, the observed C(max) following sc dosing was less than half of that after oral dosing. The sc route had the greatest overall exposure (AUC(0-infinity)). Tissue distribution analysis 2 h post-intravenous dosing showed that connective tissue (adipose and bone), liver, and skeletal muscle accumulated relatively high levels of fluasterone. The majority of the dose was retained during the first 24 h. Elimination of [14C]fluasterone-derived radioactivity following intravenous dosing resulted in urine and feces containing 7.6% and 28%, respectively, of the total dose over the first 24 h. Elimination of [14C]fluasterone-derived radioactivity following subcutaneous dosing resulted in 4.6% in urine and 7.8% in feces of the total dose over the first 24 h. Following oral dosing, elimination resulted in 3.8% in urine and 36% in feces over the first 24h. In conclusion, the sc route of administration offers some advantages to po and iv due to the prolonged release and increased retention through 24 h. 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19836365     DOI: 10.1016/j.cbi.2009.10.004

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  2 in total

1.  Toxicogenomics and metabolomics of pentamethylchromanol (PMCol)-induced hepatotoxicity.

Authors:  Toufan Parman; Deborah I Bunin; Hanna H Ng; Jonathan E McDunn; Jacob E Wulff; Abraham Wang; Robert Swezey; Laura Rasay; David G Fairchild; Izet M Kapetanovic; Carol E Green
Journal:  Toxicol Sci       Date:  2011-09-13       Impact factor: 4.849

2.  Components of the human-specific, p53-mediated "kill switch" tumor suppression mechanism are usurped by human tumors, creating the possibility of therapeutic exploitation.

Authors:  Jonathan Nyce
Journal:  Cancer Drug Resist       Date:  2019-12-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.